Table 3. Recommended doses of currently licensed formulations of adolescent and adult hepatitis B vaccines
| Group | Single-antigen vaccine | Combination vaccine | ||||
|---|---|---|---|---|---|---|
| Recombivax HB | Engerix-B | Twinrix* | ||||
| Dose (µg)† | Volume (mL) | Dose (µg)† | Volume (mL) | Dose (µg)† | Volume (mL) | |
| Adolescents aged 11–19 years§ | 5 | 0.5 | 10 | 0.5 | NA | NA |
| Adolescents aged 11–15 years¶ | 10 | 1.0 | NA | NA | NA | NA |
| Adults (aged ≥20 years) | 10 | 1.0 | 20 | 1.0 | 20 | 1.0 |
| Hemodialysis patients and other immunocompromised persons aged < 20 years§ | 5 | 0.5 | 10 | 0.5 | NA | NA |
| Hemodialysis patients and other immunocompromised persons aged ≥20 years | 40** | 1.0 | 40†† | 2.0 | NA | NA |
Sources: CDC. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part 1: immunization of infants, children, and adolescents. MMWR 2005;54(No. RR-16). CDC. A comprehensive immunization
strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR 2006;55(No. RR-16).
* Combined hepatitis A and hepatitis B vaccine. This vaccine is recommended for persons aged ≥18 years who are at increased risk for both hepatitis B and hepatitis A virus infections.
† Recombinant hepatitis B surface antigen protein dose, in micrograms.
§ Pediatric formulation administered on a 3-dose schedule; higher doses might be more immunogenic, but no specific recommendations have been made.
¶ Adult formulation administered on a 2-dose schedule.
** Dialysis formulation administered on a 3-dose schedule at 0, 1, and 6 months.
†† Two 1.0-mL doses of the adult formulation administered at one site on a 4-dose schedule at 0, 1, 2, and 6 months.